Melhem Jabbour is an Oncology physician affiliated with Saint Francis University. OpenAlex indexes 5 publications with 481 citations (h-index 4).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2723 S 7th St Ste O
Terre Haute, IN 478023562
Telephone
812-232-1418Registry record last updated 8 Aug 2014.
Industry payments
90 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202515 payments
- Novartis Pharmaceuticals CorporationProgram year202519 payments
- Merck Sharp & Dohme LLCProgram year202515 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
29.3%Factor Xa inhibitor25.1%Eliquis61%Xarelto39%Part D≥34 patientsVitamin K antagonist4.2%Warfarin Sodium100%Part D<11 patientsCancer & immunology
28.5%Aromatase Inhibitor11.2%Anastrozole89%Letrozole11%Part D<11 patientsThalidomide Analog5.6%Lenalidomide51%Pomalyst25%Revlimid25%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
17.6%Serotonin-3 Receptor Antagonist7.6%Ondansetron Hcl100%Part D≥58 patientsCorticosteroid5.9%Prednisone100%Part D≥19 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Efficacy and safety of half-dose pegfilgrastim in cancer patients receiving cytotoxic chemotherapy.
Journal of Clinical Oncology
2012 - Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma
Leukemia & lymphoma/Leukemia and lymphoma
2010
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”